Exploratory phase 3 data suggest that gefurulimab may reduce the need for rescue therapy and hospitalizations in patients ...
Diagnosis of generalized myasthenia gravis involves clinical symptoms, serologic markers, and electrodiagnostic studies, with AChR and MuSK autoantibodies being key indicators. Differentiating ...
Gefurulimab showed significant improvements in MG-ADL scores in the phase 3 PREVAIL study for anti-AChR antibody-positive gMG patients. The treatment was well tolerated, with a safety profile ...
Cemdisiran, an investigational small interfering RNA (siRNA) therapeutic targeting complement component 5 (C5), led to fewer hospitalized myasthenia gravis patients compared with placebo, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results